| Dr Krishna M Irrinki, MD | |
|
101 W University Ave, Champaign, IL 61820-3981 | |
| (217) 337-2310 | |
| Not Available |
| Full Name | Dr Krishna M Irrinki |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 101 W University Ave, Champaign, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235479783 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 036141580 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Osf Sacred Heart Medical Center | Danville, IL | Hospital |
| Osf Heart Of Mary Medical Center | Urbana, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christie Clinic, Llc | 7719899319 | 200 |
News Archive
In this interview, News-Medical talks to Santi Dominguez (SD) and Michael Graz (MG), CEOs at
Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta's experience in melanoma clinical research.
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.
› Verified 9 days ago
| Entity Name | Christie Clinic, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871523829 PECOS PAC ID: 7719899319 Enrollment ID: O20031103000332 |
News Archive
In this interview, News-Medical talks to Santi Dominguez (SD) and Michael Graz (MG), CEOs at
Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta's experience in melanoma clinical research.
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.
› Verified 9 days ago
| Entity Name | Mount Sinai Community Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376715896 PECOS PAC ID: 5991600405 Enrollment ID: O20040202001032 |
News Archive
In this interview, News-Medical talks to Santi Dominguez (SD) and Michael Graz (MG), CEOs at
Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta's experience in melanoma clinical research.
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Krishna M Irrinki, MD 101 W University Ave, Champaign, IL 61820-3909 Ph: (217) 337-2174 | Dr Krishna M Irrinki, MD 101 W University Ave, Champaign, IL 61820-3981 Ph: (217) 337-2310 |
News Archive
In this interview, News-Medical talks to Santi Dominguez (SD) and Michael Graz (MG), CEOs at
Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta's experience in melanoma clinical research.
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.
› Verified 9 days ago
Dr. Salim G. Khazoum, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave, Champaign, IL 61820 Phone: 217-337-2310 | |
Dr. Tangella V. Krishnarao, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave, Champaign, IL 61820 Phone: 217-337-2310 |